Clinical Trial Update: Drug-drug Interaction of BI 201335 and Microgynon [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the drug-drug interaction between Boehringer Ingelheim's BI 201335 (faldaprevir) and Microgynon in adults with chronic hepatitis C; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335 (faldaprevir) (faldaprevir)
• Microgynon (ethinylestradiol/levonorgestrel)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED | Results posted: 2015-08-03